Abstract
New investigational drugs and devices are commonly used in critically ill patients. The development of new drugs and the role of the critical care nurse caring for subjects in clinical trials are crucial to the success of the research process. The purpose of this article is to discuss the Food and Drug Administration's regulatory approval process for significant risk investigational devices.